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ABSTRACT: Measurements of protein higher order structure
(HOS) provide important information on stability, potency,
efficacy, immunogenicity, and biosimilarity of biopharmaceuticals,
with a significant number of techniques and methods available to
perform these measurements. The comparison of the analytical
performance of HOS methods and the standardization of the
results is, however, not a trivial task, due to the lack of reference
protocols and reference measurement procedures. Here, we
developed a protocol to structurally alter and compare samples
of somatropin, a recombinant biotherapeutic, and describe the
results obtained by using a number of techniques, methods and in
different laboratories. This, with the final aim to provide tools and
generate a pool of data to compare and benchmark analytical platforms and define method sensitivity to structural changes. Changes
in somatropin HOS, induced by the presence of zinc at increasing concentrations, were observed, both globally and at more localized
resolution, across many of the methods utilized in this study and with different sensitivities, suggesting the suitability of the protocol
to improve understanding of inter- and cross-platform measurement comparability and assess analytical performance as appropriate.
Measurements of protein higher order structures (HOS)provide information on the stability, potency, efficacy,
immunogenicity, and biosimilarity of biotherapeutics and an
insight of the dynamics and functionality of proteins.1−4 A
wide variety of techniques are available for the analysis of
protein HOS, but little is known about the comparability of the
data generated. Here, we developed, for the first time, a
protocol to prepare and progressively modify the structure of a
protein standard, to assess sensitivity to structural changes of
different analytical methodologies and enable measurement
comparability studies. This, to our knowledge, is also the first
interlaboratory comparison of its kind.
Somatropin (recombinant human growth hormone, rhGH)
was chosen as the protein model system in this study as it is a
stable, well characterized protein,5−7 with a defined HOS.
Furthermore, it is easily and reliably sourced.8,9 A reference
protocol was here developed to progressively induce localized
HOS changes via the addition of zinc salts. The effects of Zn2+
on hGH are well documented in the literature.5,10−12 Zn2+ is
known to induce dimerization of hGH in the pituitary glands,12
and its use as a precipitating agent in formulation processing
has revealed minor tertiary structural changes of rhGH.13
Hydrogen−deuterium exchange-mass spectrometry (HDX-
MS), ion mobility spectrometry-mass spectrometry (IMS-MS),
size exclusion chromatography (SEC) and thermal stability
experiments were first carried out to define the experimental
conditions to consistently induce rhGH structural changes via
Zn2+. An interlaboratory comparison was then organized,
where data were acquired by HDX-MS, IMS-MS, Raman
spectrometry (Raman), analytical ultracentrifugation (AUC),
circular dichroism spectroscopy (CD), capillary zone electro-
phoresis (CZE), thermal stability, and biological activity
measurements, to assess the potential of the protocol to be
used to define instrument performance and carry out
comparability measurements across platforms.
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Chemicals and Reagents. All chemicals and standards
were purchased from Sigma-Aldrich [Gillingham, U.K.] and
were of research grade purity unless otherwise stated.
Ultrapure water (18 MΩ cm−1) was used. For buffer and
sample preparation, monobasic and dibasic potassium
phosphate and HPLC grade water were purchased from
Acros Organics [Belgium].
The following materials were supplied to each participating
laboratories: ampules each containing 1.9 mg of lyophilized
rhGH standard [WHO 98/574, NIBSC, U.K.]; vials
containing, respectively, 0.165 g of zinc acetate, 0.18 g of
potassium phosphate monobasic, and 0.64 g of potassium
phosphate dibasic; 1 L of HPLC grade water; one protein low
binding Eppendorf [Eppendorf, U.K.]. All samples and
reagents were shipped at room temperature with details on
the handling of the samples, sample preparation, and storage as
described in the Supporting Information.
Participating Laboratories and Analytical Methods.
Thirteen laboratories participated in the interlaboratory
comparison, with some laboratories providing multiple data
sets from different analytical platforms. Participants were
supplied with one of three working instructions (WI), for
generic, HDX-MS, and IMS-MS analytical based platforms
(Supporting Information), with a detailed description of
protein sample preparation, some desired analytical conditions,
and a report formatted to feedback methods and results.
Participants were assigned a random and anonymized number,
from 1 to 13.
Overall the analysis of rhGH control, rhGH:Zn 1:2 and
rhGH:Zn 1:10 was performed using 10 techniques: analytical
ultracentrifugation, (AUC, Beckman Coulter proteomeLab
XL-I), laboratory 9; capillary zone electrophoresis (CZE-UV,
Beckman Coulter P/ACE System MDQ), laboratory 8;
circular dichroism (CD, AVIV Biomedical 430 CD spectro-
photometer), laboratory 11; differential scanning calorimetry
(DSC, MicroCal VP DSC spectrometer), laboratory 9;
intrinsic protein fluorescence (IPF, Varian Cary Eclipse
spectrophotometer), laboratory 9; melting point fluorescence
(Tm, Unchained Laboratories Optim and UNit systems),
laboratory 13; HDX-MS (PAL HDX automation robot with
Synapt G2Si or G2S, see Table S2), laboratories 1−4 and 12;
IMS-MS (Waters Synapt G1/G2/G2Si instruments), labo-
ratories 1, 3, 5, and 6; Raman (Renishaw inVia confocal Raman
microscope), laboratory 7; SEC-UV (Agilent 1000 series
HPLC), laboratory 1; Nb2.11 cell-based bioassay (CellTiter-
Glo, Promega), laboratory 10.
Details in full for each analytical methodology, analysis, and
any deviations from the WI for sample preparation can be
found in the Supporting Information.
■ RESULTS AND DISCUSSION
Development of Reference Protocol. Characterization
of Secondary Structure Changes by HDX-MS. The secondary
structure of rhGH was initially determined by HDX-MS
experiments. In order to define measurement variability and
establish measurement thresholds that discriminate changes in
structural dynamics from HDX-MS measurement variability, a
vial-to-vial study of rhGH was carried out. The differential
HDX-MS measurements from triplicate interday data sets were
processed using the statistical approach described by Groves et
al.14 In Table S8, the raw peptide level thresholds are
displayed. Differential HDX-MS experiments were then carried
out to compare the structural dynamic of rhGH in the absence
and presence of zinc also by using a statistical approach as
described by Groves et al.14
The differential sums (relative measurements summed
across all incubation periods) for each peptide were calculated
for the comparison of (a) rhGH control and rhGH:Zn 1:2 and
(b) rhGH control and rhGH:Zn 1:10 (Figure S-1 and Table
S8). Based on the calculated thresholds,14 two peptides were
identified in part (a) and 13 peptides in part (b) as
representative of significant changes in structural dynamics of
rhGH induced by the presence of zinc (Table 1).
For the rhGH:Zn 1:2 sample, the two relevant peptides
demonstrating changes in dynamics are located in region II,
which is helix A of rhGH (Figure 1 and Figure S-1), where two
of the three residues reported to be involved in the Zn2+
binding to rhGH are also located (His18 and His21).5,10
Increasing the concentration of zinc to obtain a ratio rhGH:Zn
equal to 1:10 confirmed the structural differences identified for
the rhGH:Zn 1:2. Furthermore decreased HDX kinetics were
observed at the N- and C-terminal regions (regions I and V) of
the polypeptide chain, suggesting long-range changes in
structural dynamics (Figure 1 and Figure S-1).
Structural destabilization in the form of increased HDX
kinetics was also observed for regions III and IV in the
presence of zinc, corresponding to both a loop region and part
of helix C, respectively. All regions identified as showing
dynamic changes due to the presence of zinc appeared to
exhibit EX2 kinetics in both the absence and presence of zinc
suggesting stable folded conformations on these time scales.
Definition of the Protocol for Sample Preparation. To
ensure that the experimental conditions for the preparation of
rhGH were adequate for the interlaboratory comparison and
for the operative conditions of the diverse analytical platforms,
additional experiments were carried out by SEC, IMS-MS, and
IPF (using Optim platform). To ensure that dialysis had no
significant effect on protein HOS, the thermal stability of
Table 1. rhGH Peptides Identified as Showing Significant












1 1−9 FPTIPLSRL − I
2 2−9 PTIPLSRL − I
4 14−25 MLRAHRLHQLAF + II
5 15−25 LRAHRLHQLAF + + II
6 16−25 RAHRLHQLAF + II
7 26−32 DTYQEFE + + II
26 93−100 LRSVFANS + III
34 114−124 LKDLEEGIQTL + IV
35 115−124 KDLEEGIQTL + IV
36 117−124 LEEGIQTL + IV
51 178−191 RIVQCRSVEGSCGF − V
52 182−191 CRSVEGSCGF − V
53 183−191 RSVEGSCGF − V
aChanges are expressed as HDX increases (+) and decreases (−)
relative to rhGH control; no significant change is indicated by blank
input.
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rhGH samples was measured using IPF in both dialyzed and
nondialyzed forms. Both samples exhibited the same change in
fluorescence intensity (FLI) over temperature profiles, with a
transition starting around 75 °C and a melting temperature
(Tm) of 78.1 ± 0.001 °C (Figure S-2), suggesting consistent
structures.
SEC-UV measurements were performed at two different
concentrations of rhGH control (7.2 and 36 μM) covering the
range of concentrations required for the diverse analytical
experiments to monitor for the presence of aggregates. A peak
eluting prior to the rhGH monomeric peak (∼22 kDa) and
attributed to rhGH dimers (∼44 kDa) was consistently
measured as ≤0.5% of rhGH signal across all samples (Figure
S-3).
Native IMS-MS experiments were also carried out to
monitor for the formation of potential hGH dimers induced
by an increasing amount of zinc. Also in this case, the dimer
population observed was consistently less than 0.5% (Figure S-
4).
Finally, the solubility of zinc acetate in KPBS was verified by
measuring the content of soluble zinc by inductively coupled
plasma optical emission spectrometry (Supporting Informa-
tion). The measured content of zinc in the vials was within the
expected measurement uncertainty.
Zn2+-rhGH binding was confirmed by native IMS-MS
measurements (Figure S-4). Stochastic binding ratios of 1:1,
and both 1:1 and 1:2 were observed for rhGH:Zn 1:2 and 1:10
samples, respectively. A control sample containing rhGH in the
presence of ten molar equivalents of Mg2+ (rhGH:Mg 1:10)
was also analyzed by native IMS-MS. The results showed
reduced binding of the Mg2+ compared to Zn2+, confirming the
specific binding of zinc (Figure S-4).
Interlaboratory Comparison Results. HDX-MS. Bottom
up HDX-MS analysis was performed by five laboratories, with
little guidance provided with respect to the experimental
parameters (only a suggested incubation range) as for the
other techniques used in this study. This was to define the
potential utility of the rhGH:Zn protocol to aid method
development and to assess instrument performance in different
conditions and for diverse purposes.
Peptide maps from HDX-MS measurements submitted by
the five laboratories varied in terms of the number of peptides
(35−68), sequence coverage (82.2−96.9%), and redundancy
of overlapping peptidic sequences (2.20−4.20) as different
methods were used.14,15 However, the sequence coverage
across all data sets allowed for monitoring of most of the rhGH
structure (Table S9 for individual laboratory sequence
coverage data and Tables S1−S5 for experimental conditions),
and comparable changes in the structural dynamics were
observed particularly for the rhGH:Zn 1:10 sample.
The HDX-MS data from the different laboratories were also
submitted as raw data and processed by the coordinating
laboratory for comparison. For this, two tools widely used by
the scientific community were applied, the commercially
available DynamX software (based on the 3σ approach) and
the freely available online MEMHDX software.16 The HDX-
MS data from laboratory 1, which were used to establish the
protocol, were also reprocessed alongside the other data sets.
Details on the parameters used for the statistical approaches
are described in the Supporting Information. Regions
identified as showing significant changes in dynamics using
interpretation by DynamX or MEMHDX are indicated in
Figure 2 and Figures S-5 and S-6. At higher concentrations of
zinc, changes in the protein dynamics were observed by all
laboratories as shown in Figure 2 and Figure S-5. Furthermore,
by using the MEMHDX approach, subtle changes in kinetics
(∼≤5%) were observed for the rhGH:Zn 1:2 by all
laboratories and a decreased HDX kinetics at the N-terminal
region of rhGH was also identified (Figure S-6).
Overall the results from laboratories 1−4 processed by
DynamX and MEMHDX also agreed with the results from
laboratory 1 processed by applying the statistical approach
described by Groves at al.14
Figure 1. Relative differences in HDX-MS measurements between
rhGH control and rhGH:Zn 1:10 samples. (a) Increased (red),
decreased (blue), and unchanged (gray) HDX rates are indicated on
the XRC structure of rhGH (PDB 1BP35). Missing peptidic
sequences are indicated in black. A bound zinc ion is indicated as a
sphere. Labeled regions include the following residues: region I [1−
9], II [14−32], III [98−106], IV [114−124], V [178−191]. (b) Zinc
binding residues His18, His21, and Glu174 are illustrated by stick
representations. Measurements were provided by laboratory 1, and
relative changes were deemed significant using thresholds established
using a vial-to-vial approach.14
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One laboratory performed HDX-MS measurements using
incubation periods in the ms−1−s−1 range (Table S1, Figures
S5 and S9) by using the setup described by Kish et al.18 This is
an experimental approach which facilitates insights into more
flexible/unstructured regions of a protein that fully deuterates
using a ≥millisecond time scale.17−19 Also in this case,
structural differences were observed in the presence of zinc
(Figure S-5). These data were consistent with the Zn-
dependent slower kinetics (same sign and similar magnitude)
observed for N- and C-terminal regions identified across the
other data sets. Although, in some cases, spectral envelopes
indicate kinetics belonging to a mixed protein population were
observed, there was a major species with EX2 behavior (Figure
S-7), therefore deuterium uptake differences were calculated
with the same method as for other data (delta centroid).
Furthermore, as expected, the increased kinetics observed for
the central region of helix A in the presence of zinc, only
observed at later incubation periods during the conventional
>s−1 HDX experimental setup were not observed using these
shorter incubation periods. Further experiments outside the
scope of this paper should be carried out both to confirm this
and to determine if millisecond-mixing introduced a mixing
artifact or if there is evidence of a meaningful mixed protein
population under HDX labeling conditions (e.g., monomer/
dimer).
Native IMS-MS. Native IMS-MS measurement revealed
three different conformations of rhGH: a compacted
monomer, an extended monomer, and a dimeric species, as
reported for all rhGH and rhGH:Zn samples by all four
participating laboratories. Agreement between laboratories was
also observed for stoichiometries of 1:1 and 1:2 rhGH:Zn with
an increased propensity of the 1:2 binding ratio for the
rhGH:Zn 1:10 sample.
Reported collisional cross section (TWCCSN2) measurements
for the +9 charge state of rhGH and rhGH:Zn samples, as well
as instrumentation used, are summarized in Table 2. All
measurements were performed using the Synapt Tri-Wave
instrument series [Waters, Milford] of varying generations. An
apparent correlation between the IMS-MS instrument
generation and reported TWCCSN2 measurements of the
rhGH control appears to exist, with measurements in the
range ∼2100 and ∼2400 Å2 for earlier generation (HDMS/
G2) and G2Si Synapt instrumentation, respectively, suggesting
instrumental bias on measurements. TWCCSN2 measurements
of rhGH using a HDMS instrument are consistent with
previously published TWCCSN2 measurements of 2077 ± 230
Å2.20 Though changes in TWCCSN2 measurements between the
rhGH and rhGH-Zn bound species were only reported by two
laboratories, measurements from all laboratories demonstrated
narrower full width half-maximum (fwhm) for arrival time
distribution of IMS-MS measurements of the ≥+9 charge state
in rhGH:Zn 1:10 samples for singly rhGH-Zn bound species,
relative to rhGH control and rhGH:Zn 1:2 samples (Figure S-
8). These data suggest the distribution of species present is
more stable and compact when zinc is bound.
Two laboratories (1 and 5) also performed collisional
activation (CA)-IMS-MS experiments carried out on free and
zinc bound charge species of rhGH, whereby both data sets
revealed an increase in stability ∼2 V against unfolding for the
zinc bound species relative to the free species, Figure S-9.
Overall an apparent global stabilization of rhGH in the
presence of zinc was observed with no large global structural
rearrangement.
Raman Spectroscopy. Following dialysis and dried spot
preparation, Raman spectra were recorded for all rhGH and
rhGH:Zn samples. Analysis of measurements of the rhGH
control and rhGH:Zn 1:2 and 1:10 samples allowed subtle
differences between the samples to be observed at some
specific wavenumbers. Suggested peak assignments have been
made for these regions of changes in shift intensity (Figure 3,
Table S10). In particular, small changes in peak intensity were
Figure 2. Relative deuterium uptake differences obtained by
laboratories 1−4 as indicated when considering differential HDX-
MS measurements between the rhGH control and rhGH:Zn 1:10
samples. Relative changes were deemed significant using the
MEMHDX software tool. Increased (red), decreased (blue), and
unchanged (gray) HDX rates of specific peptides are indicated on the
sequence of rhGH with highlighted helices A, B, C, and D. Regions
which are indicated as showing consistent structural changes across
≥3 laboratories are highlighted in boxes. The spheres indicate zinc
binding residues.
Table 2. Reported TWCCSN2 Measurement Values for the +9
Charge State of rhGH Control and rhGH:Zn Bound
Speciesa
lab





1 Synapt G2Si 2482 ± 162 2480.9 ± 161 2486.6 ± 162
3 Synapt G2Si 2322.2 ± 19 2264.5 ± 6 2269.0 ± 11
5 Synapt
HDMS
2129 ± 48 2135 ± 50 2106 ± 52
6 Synapt G2 2103 ± 12 2088 ± 9 2019 ± 2
aAll measurements were performed using Synapt Tri-Wave based
IMS instruments of varying generations as stated. Uncertainty values
stated were generated by the participating laboratory.
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observed at 1206, 1607, and 1652 cm−1 for the rhGH:Zn 1:10
sample compared to the rhGH control and rhGH:Zn 1:2
samples, associated with the loss of a buried α-helical structure
and changes in orientation of tyrosine and phenylalanine side
chain residues.21−23 These spectral changes, although subtle,
potentially correspond to a change in conformation for a
buried α-helical structure which would be consistent with the
zinc binding site located at helices A and D and observations of
HDX-MS measurements.
CD. CD measurements of 36 μM rhGH samples were shown
to be reproducible across all samples and replicates (Figure S-
10). The relative percentage content of various secondary
structural features as determined from the CD data are as
follows (α-helical, β-sheet, turns, unstructured): rhGH control
(61%, 3%, 14%, 22%), rhGH:Zn 1:2 (60%, 3%, 14%, 23%),
and rhGH:Zn 1:10 (57%, 3%, 16%, 24%); hence, all samples
were predominantly α-helical in structure. Secondary struc-
tures of the rhGH control and rhGH:Zn 1:2 samples were
equivalent; however, for the rhGH:Zn 1:10 samples, the α-
helix content was lower by 4%, with concomitant increases of
2% in both turn and unstructured types, indicating a modest
but significant structural change at this concentration of zinc.
These data are consistent with HDX-MS and Raman
measurements which demonstrate a loss of the α-helical
structure upon zinc binding.
Capillary Zone Electrophoresis. Analysis by CZE-UV
revealed two peaks in the CZE profiles of each rhGH and
rhGH:Zn samples, one peak attributed to excipients and the
other to the monomeric rhGH (Figure S-11), as demonstrated
by ultrafiltration experiments and consequent injection of the
retained and filtrated samples in CZE (data not shown, see the
Supporting Information). Reproducible electrophoretic mobi-
lities were observed across all rhGH and rhGH:Zn samples,
suggesting consistent globular structures across the samples.
Intrinsic Fluorescence. Tertiary structural changes between
the rhGH and rhGH:Zn 1:10 samples were monitored using
intrinsic tryptophan fluorescence whereby no shift in λmax was
observed across the rhGH samples (Table S11) suggesting no
sensitivity of the technique to tertiary structural changes upon
Zn2+ binding.
Thermal Stability. Two different analytical platforms, UNit
and DSC, were used to assess the thermal stability of rhGH
and rhGH:Zn samples, measurements are summarized in
Table 3. Overall high measurement comparability was shown
by the two thermal stability platforms for the rhGH:Zn 1:10
samples, a consistent and reproducible increase in Tm of ∼1 °C
for rhGH:Zn 1:10 samples compared to the rhGH control, at
25 and 36 μM concentrations, was reported for both platforms.
A smaller (∼0.3 °C) but reproducible increase in Tm for
rhGH:Zn 1:2 samples compared to the rhGH control was
measured by DSC only (Figure S-12). These data suggest an
increase in global stability in the presence of zinc, with the
magnitude of global stabilization increasing at higher zinc
concentrations. No evidence of temperature induced aggrega-
tion was observed for the samples at either concentration.
Analytical Ultracentrifugation (AUC). AUC analysis
measured the Stokes radii of the rhGH control sample to be
2.37 nm, with a decreasing Stokes radii observed upon the
Figure 3. Averaged Raman spectra (n = 6) of dialyzed rhGH samples, rhGH control (black), rhGH:Zn 1:2 (red), and rhGH:Zn 1:10 (blue) after
preprocessing (normalized, baselined, and smoothed). Selected wavenumbers showing intensity shifts across samples are indicated.
Table 3. Summary of Melting Temperatures (Tm) Measured for rhGH Control, rhGH:Zn 1:2, and rhGH:Zn 1:10 for Two
Different Analytical Platformsa
Tm (°C)
platform rhGH concentration rhGH control rhGH:Zn 1:2 rhGH:Zn 1:10
UNit 36 μM 81.20 ± 0.25 82.00 ± 0.50 82.20 ± 0.20
DSC 25 μM 78.79 ± 0.06 79.08 ± 0.15 79.99 ± 0.20
aSample concentration and platform are indicated; method details can be found in the Supporting Information.
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addition of zinc to rhGH, of ∼1.8 and 7.1% for rhGH:Zn ratios
of 1:2 and 1:10, respectively (Table S12, Figure S-13),
suggesting the global structure of rhGH has become more
spherical/compact in increasing presence of zinc. Other than a
change in conformation, a shift in the distribution of
monomer/dimer populations could account for this change
in Stokes radii. However, this was ruled out as no evidence of
aggregation was observed with the addition of zinc, upon visual
inspection of the sample nor by SEC-UV or thermal
denaturation measurements.
Nb2.11 Cell-Based Bioassay. Assay measurements were
performed across the 0.35−45 nM range using two Nb2.11
cell-based bioassays. No change in activity was observed for
rhGH preincubated in the presence zinc at rhGH:Zn ratios of
1:2 and 1:5 relative to the rhGH control. While no change in
activity was observed across the samples, it has to be
considered that the extensive dilution of the samples and the
need to perform the bioassay in a complex assay medium
(including Fishers medium and 1% v/v/heat-inactivated
horse’s serum) may have altered the availability of the zinc
ions. A secondary assay measuring the proliferative response of
Nb2.11 cells upon the direct addition of zinc acetate, saw a
reduced cellular response. However, this was deemed
insignificant due to the evidence of increased cell death in
negative controls containing zinc acetate only. Additionally it is
possible that the changes in HOS may have no impact on the
activity of rhGH in the assay.
Comparability of Results. Table 4 summarizes the results
from the interlaboratory comparison and the suitability of the
protocol to assess the sensitivity to structural changes and
structural dynamics of diverse analytical platforms. Particularly
HDX-MS, IMS-MS, DSC, and AUC measurements showed
structural changes of rhGH at both concentrations of zinc. In
contrast, measurements performed by more routine analytical
platforms such as the SEC-UV, CZE, and IPF measurements
were unable to detect any structural changes using this model
system. Induced changes in structural dynamics were
reproducibly resolved to specific regions of the rhGH structure
by HDX-MS measurements performed in multiple laborato-
ries, despite the nonstandardized conditions. A particular
correlation was seen across HDX-MS, CD, and Raman
spectroscopic measurements and provided complementary
information. A loss in helical structure upon the addition of
zinc was observed, suggesting localized structural changes
induced by the protocol, though HOS changes remain
unresolved to regions for CD and Raman data sets. Similarly,
native IMS-MS, thermal stability, and AUC measurements
indicated a small and consistent globular structural change,
though with varying sensitivity.
■ CONCLUSIONS
A protocol to assess sensitivity to protein HOS changes and
validate analytical platforms used for measuring those changes
was here successfully developed and its validity demonstrated
across a number of analytical platforms. To our knowledge, this
is the first protocol and interplatform study of its kind that
enable a comparability investigation of HOS measurements
across a plethora of methodologies, including established and
emerging technologies, spanning the breadth of the bio-
pharmaceutical toolbox for HOS measurements. The range of
resolution and sensitivity observed across platforms illustrates
the struggles of the biopharmaceutical industry when met with
the task of providing sufficient evidence to regulators for the
continuity of protein structure during both R&D and
manufacturing stages of drug development. Rather these data
demonstrate the need for multiple sources of measurements to
be used in conjunction with one another. The availability of
suitable quality control materials to provide such evidence to
regulators and industry will be a key component in its more
widespread adoption (alongside easier/more accessible data
analysis) within this setting. Undoubtable similar protocols and
approaches should be developed for a broader range of
Table 4. Summary of the Sensitivity of the Range of Analytical Platforms and Methods Across the Interlaboratory Comparison
Towards Relative Structural Changes between rhGH Control Sample and rhGH:Zn Samples at Ratios of 1:2, 1:5, and 1:10a
aPositive (green), negative (red), and nonapplicable (blank) identification of a structural change are indicated, as are Lab ID, sample concentration,
the type of structural information gained during the analyses and if dialysis of the sample was performed prior to analysis (Y, yes or N, no).
Structural changes as indicated with an * using MEM-HDX data analysis workflows to assess data significance.
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bioproducts, including monoclonal antibodies. Those studies
will provide complementary tools and information to the one
generated from standardized interlaboratory comparisons to
assess the reproducibility of methods such as the HDX-MS
interlaboratory comparison described in Hugdens et al.24
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